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Abstract
Introduction: Hyperglycemia and protein loss are common in critically ill patients. Insulin can be used to lower
blood glucose and inhibit proteolysis. The impact of moderate insulin therapy on protein metabolism in critically ill
patients has not been evaluated. We compared urinary nitrogen excretion, nitrogen balance, serum albumin
concentrations, prealbumin concentrations, and clinical outcomes between patients receiving moderate insulin
therapy (MIT) and conventional insulin therapy (CIT) in a medical ICU.
Methods: Patients were randomly divided into groups and treated with MIT (glucose target 120 to 140 mg/dl) or
CIT (glucose target 180 to 200 mg/dl). Calories and protein intake were recorded each day. On days 3, 7 and 14,
the 24-hour urinary nitrogen excretion, nitrogen balance, and serum albumin and prealbumin concentrations were
measured. Clinical outcomes data were collected.
Results: A total of 112 medical ICU patients were included, with 55 patients randomized to the MIT group and 57
patients randomized to the CIT group. Patients treated with MIT showed a trend towards increased nitrogen
balance (P = 0.070), significantly lower urinary nitrogen excretion (P = 0.027), and higher serum albumin (P = 0.047)
and prealbumin (P = 0.001) concentrations than patients treated with CIT. The differences between the two groups
were most significant on day 3, when all factors showed significant differences (P < 0.05).
Conclusions: Moderate glucose control results in less negative nitrogen balances in medical ICU patients.
Differences are more significant in the early stages compared with the late stages of critical illness.
Trial registration: ClinicalTrial.Gov NCT 01227148
Introduction
Hyperglycemia, which is common in critically ill
patients, occurs even in those patients who have not
previously had diabetes [1,2]. Critical illness is associated
with increased circulating concentrations of proinflam-
matory cytokines, such as TNFa, IL-1, and IL-6, which
may be important mediators of insulin resistance and
hyperglycemia [3]. Altered glucose metabolism results
from the release of counter-regulatory hormones. Epi-
nephrine and cortisol oppose the normal action of insu-
lin, leading to increased adipose tissue lipolysis and
skeletal muscle proteolysis [4]. Reports state that
pronounced hyperglycemia may lead to complications or
a poor clinical outcome in such patients [5,6]. The
maintenance of normoglycemia using insulin therapy
has been shown to significantly reduce morbidity and
mortality in critically ill patients [5,7,8]. However, some
studies failed to demonstrate improved outcome [9-12],
and even a higher mortality rate was found [13] Inten-
sive insulin therapy has been associated with a signifi-
cantly higher risk of hypoglycemia [5,7], resulting in
concern regarding the safety of intensive insulin therapy.
Glycemic control to a moderately tight range is not
inferior to euglycemia and is clearly safer in critically ill
patients [14]. Patients with glucose levels of 130 mg/dl
were reported to have a significantly lower incidence of
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Protein loss, which is also common in critically ill
patients, is thought to arise from both increased proteo-
lysis [16] and diminished protein synthesis [17]. Protein
wasting can negatively affect patient outcome [18]. The
use of insulin to promote an anabolic response during
critical illness is a promising therapeutic approach. Ani-
mal studies have shown that strict insulin therapy nor-
malizes organ nitrogen contents in diabetic rats [19].
Woolfson and colleagues demonstrated that insulin has
important protein-sparing effects in severely ill trauma
patients [20]. Shiozaki and colleagues showed that burn
patients who received higher doses of insulin maintained
a better nitrogen balance than a lower-dose group [21].
The purpose of this study was to investigate the differ-
ences in urinary nitrogen excretion, nitrogen balance,
serum albumin and prealbumin concentrations, and
clinical outcomes between moderate insulin therapy




This study was a prospective, randomized, controlled
trial conducted in an adult medical ICU of a tertiary
medical center that has 1,235 beds in total, 59 of which
are adult ICU beds. Trial and consent forms were
approved by the Institutional Review Board of Kaoh-
siung Veterans General Hospital. The study was carried
out between January 2006 and December 2006. Proce-
dures were in accordance with the Helsinki Declaration.
Subjects
Patients aged 18 or over who were admitted to the med-
ical ICU with blood glucose concentrations over 180
mg/dl were eligible for inclusion. The criteria for exclu-
sion included prior surgical treatment, pregnancy, parti-
cipation in another study, patients with chronic renal
loss, and patients who were expected to require treat-
ment in the ICU for less than 4 days. Chronic renal loss
was defined as persistent acute renal failure with the
complete loss of kidney function for more than 4 weeks
[22]. The first author (C-WH) enrolled participants. A
total of 283 patients were evaluated and 171 patients
were excluded. The remaining 112 patients were eligible
for the study (Figure 1).
Insulin therapy
After informed consent was obtained from patients or
the next of kin, patients were randomly assigned to
receive either MIT or CIT using software-generated
simple randomization procedures (computerized ran-
dom number) without blocking. Except for the inter-
ventionists (nurses and doctors), patients and other
staff members were not informed of the group
assignments. In the MIT group, continuous insulin
infusion was started when the blood glucose concen-
trations exceeded 140 mg/dl in order to maintain a
blood glucose concentration between 120 and 140 mg/
dl. The insulin dose was adjusted using a neuro-fuzzy
method; the insulin protocol is shown in Additional
file 1. In the CIT group, continuous insulin infusion
was delivered when blood glucose concentrations
exceeded 200 mg/dl; the insulin dose was then
adjusted to maintain a blood glucose concentration
between 180 and 200 mg/dl.
All patients were fed either intravenously (total par-
enteral nutrition) or enterally starting the day after ICU
admission. Enteral feeding was attempted as early as
possible at the discretion of the attending physician.
Once enteral feeding was started, patients were adminis-
tered full-strength isotonic commercial formula Jevity
(Abbott Laboratories, Brockville, ON, Canada) commen-
cing at 20 ml/hour, and increased by 20 ml/hour every
4 hours to satisfy energy and protein requirements
recommended by the clinical dietitian following the
Canadian clinical practice guidelines for critically ill
patients [23]. All patients did not receive an albumin
infusion during the study period.
Data collection
At the time of randomization, demographic data and
clinical characteristics were obtained. Blood glucose
concentrations were measured upon admission and,
subsequently, every 1 to 4 hours in all patients. Baseline
serum albumin concentrations, prealbumin concentra-
tions (Hitachi 7600; Hitachi, Tokyo, Japan), serum crea-
tinine, and 24-hour urinary urea nitrogen (UUN) levels
were collected and evaluated after beginning the study,
and these data were collected and evaluated on days 3,
7, and 14 of the study. Additionally, we used full 24-
hour urine collection rather than spot urine samples to
determine the UUN. Blood cultures were obtained
whenever the central body temperature exceeded 38.5°C
or other clinical signs of sepsis were present. Blood
transfusions were conducted according to the protocol
when hemoglobin levels decreased to below 7 g/dl and
were continued until target hemoglobin levels of 7 to 9
g/dl were attained. A higher hemoglobin level was
required in patients with special circumstances; for
example, myocardial ischemia, severe hypoxemia, acute
hemorrhage, or lactic acidosis [24].
From the time of randomization to the time of dis-
charge from the ICU, daily caloric and protein intakes,
all blood glucose measurements, doses of insulin, red-
blood-cell transfusions, blood cultures that were positive
for pathogenic organisms, renal function, gastrointestinal
bleeding, moderate hypoglycemia, and severe hypoglyce-
mia were recorded.
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Definitions
Patients were classified as having diabetes on the basis
of their medical history. Previous treatment with corti-
costeroids was defined as treatment with systemic corti-
costeroids for 72 hours or more immediately before
randomization. Sepsis was defined by the presence of
both infection and a systemic inflammatory response
[25]. Acute renal injury was defined when serum creati-
nine concentrations increased by 2.0 times or the
glomerular filtration rate decreased by more than 50%
[22]. Creatinine clearance was calculated using the
Cockcroft-Gault equation [26]:
(
140− age (years))×bodyweight (kg)×0.85 (if female) /72×serum creatinine (mg/dl)
Bloodstream infection was diagnosed either when a
recognized pathogen was isolated from a blood culture,





























283 patients evaluated 
171 were excluded: 
21 were participating  
  in another study 
64 could not provide 
informed consent   
24 were expected to stay 
in ICU < 4 days 
55 were chronic renal 
loss 
7 were postoperative 
112 underwent randomization 
57 were assigned to 
conventional insulin therapy 
55 were assigned to 
moderate insulin therapy 
57 were included in 
intention-to-treat analysis 
55 were included in 
intention-to-treat analysis 
Figure 1 Assessment, randomization, and follow-up of the study patients. For detailed characteristics of randomized patients, see Table 1.
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hypotension and any of the following: a common skin
contaminant isolated from two blood cultures that were
drawn on separate occasions; a common skin contami-
nant isolated from the blood culture of a patient with
an intravascular access device, and the physician insti-
tuted appropriate antimicrobial therapy; or a positive
antigen blood test [27].
Gastrointestinal bleeding was defined as the presence
of hematemesis, melena, bright red blood per rectum, or
a coffee grounds-like substance that was aspirated from
the feeding tube. Patients with hypoglycemia were
defined as those who developed at least one episode of
hypoglycemia. A moderate hypoglycemic event was
defined as a blood glucose concentrations ≤ 60 and > 40
mg/dl. A severe hypoglycemic event was defined as
blood glucose concentration ≤ 40 mg/dl.





)− (UUN + 4)
The difference in daily insulin dose between the two
groups was the total mean insulin dose of the MIT
group minus the total mean insulin dose of the CIT
group on the same day.
Outcomes
Primary outcomes included 24-hour UUN levels, nitro-
gen balance, serum albumin concentrations, and preal-
bumin concentrations. Secondary outcomes included
ICU days, ventilator days, hospital days, acute renal
injury, bloodstream infection, blood transfusions, gastro-
intestinal bleeding, moderate hypoglycemia, severe hypo-
glycemia, and hospital mortality rate.
Statistical analysis
All data were analyzed by SPSS version 12.0 (SPSS, Inc.,
Chicago, IL, USA). Data are presented as the mean ±
standard deviation, median (interquartile range), or
number (percentage). All data were analyzed according
to the intention-to-treat principle. To detect differences
of nitrogen balance using a two-sided 5% significance
level and a power of 85% when the difference and stan-
dard deviation were equal to 0.80 and 1.97, a sample
size of 55 patients per group was necessary. This value
was based on previous studies involving nitrogen bal-
ance and different doses of insulin treatment in a burn
ICU [21]. Primary outcomes, such as 24-hour UUN
levels, nitrogen balance, serum albumin concentrations,
and prealbumin concentrations were analyzed with a
generalized linear model for repeated measures using
dummy variables. Student’s t test was used to compare
continuous variables with normally distributed data.
Wilcoxon’s rank-sum tests were used to compare
continuous variables with non-normally distributed data.
Chi-square tests were used to compare dichotomous




All participants were recruited from April 2006 to
December 2006. This trial ended when it reach the sam-
ple size goal. Of the 112 patients randomized to the
study, 55 patients received MIT and 57 patients received
CIT. All patients were available for the intention-to-treat
analysis (Figure 1). Table 1 shows the patient baseline
characteristics of all the patients enrolled in the study.
Demographic data at the time of randomization showed
no significant differences in any of the parameters. Figure
2 shows serum creatinine, creatinine clearance, and urine
output during the study period between the two groups;
there were no significant differences. The two groups
shared similar background characteristics.
Nutrition and blood glucose control
Actual daily protein (grams per day and per kilogram of
body weight) and caloric (calories per day and per kilo-
gram of body weight) intake, blood glucose concentra-
tions, and insulin dose (per hour corrected for caloric
intake) are shown in Figure 3. Daily protein and caloric
intake progressively increased until day 5, but then fluc-
tuated after day 5 in both groups. The two treatment
groups had similar protein and caloric intakes. The
mean blood glucose concentration was 125.3 ± 2.4 mg/
dl in the patients of the MIT group and 199.9 ± 4.0 mg/
dl (P < 0.01) in the patients of the CIT group. The med-
ian daily insulin dose was 82 (69 to 111) units/day in
the patients of the MIT group and 37 (26 to 43) units/
day (P < 0.01) in the patients of the CIT group (Table
2). To maintain the low blood glucose concentrations,
patients in the MIT group were administered a signifi-
cantly higher insulin dose than patients in the CIT
group. The insulin requirement per calorie decreased
each day in both groups (Figure 3). The difference in
mean daily insulin doses between the two groups ranged
from 58 IU/day on day 1 to 43 IU/day on day 14. The
difference in insulin requirements per day between the
two groups decreased each day (Figure 4).
Primary outcomes
Both groups showed a trend of decreasing levels of
excreted urinary nitrogen, better nitrogen balance, and
increasing serum albumin and prealbumin concentrations
during their hospital courses. A generalized linear model
for repeated measurements using dummy variables
revealed that there were significantly lower 24-hour urine
nitrogen excretion (P = 0.027) (Figure 5) and higher
Hsu et al. Critical Care 2012, 16:R56
http://ccforum.com/content/16/2/R56
Page 4 of 13
serum albumin (P = 0.047) and prealbumin (P = 0.001)
concentrations (Figure 6) during the study period in the
MIT group. The MIT group exhibited a higher nitrogen
balance than the CIT group; however, this difference was
not statistically significant (P = 0.070). Differences in 24-
hour urine nitrogen excretion, nitrogen balance, serum
albumin concentrations, and prealbumin concentrations
between the two groups were most significant on day 3
when all factors showed significant differences (P < 0.05).
These differences decreased after day 3.
Secondary outcomes
There were no statistically significant differences in ICU
days, ventilator days, hospital days, rate of acute renal
injury, bloodstream infection, red-blood-cell transfusion,
and gastrointestinal bleeding in the two groups (Table 2).
Moderate hypoglycemia (blood glucose levels ≤ 60
mg/dl and > 40 mg/dl) occurred more often in the MIT
group than in the CIT group, but this difference was
not statistically significant (18.2% vs. 10.5%, P = 0.10;
2.4 episodes vs. 1.5 episodes per 100 treatment days, P
= 0.18) (Table 2). The CIT group also exhibited a lower
rate of severe hypoglycemia (blood glucose levels ≤ 40
mg/dl), but the difference was not significant (3.6% vs.
1.8%, P = 0.53; 0.3 episodes vs. 0.2 episodes per 100
treatment days, P = 0.44). No hemodynamic deteriora-
tion, convulsions, or neurological sequelae were noted
in association with any hypoglycemic event in either
group.
Patients with MIT had a trend for lower hospital mor-
tality rate than that of patients with CIT, but they did
not reach a statistically significant difference.
Table 1 Demographic data for all patients
Characteristic MIT group (n = 55) CIT group (n = 57) P value





Gastrointestinal or liver 2 3
Hematologic or oncologic 3 1
Renal 1 2
Metabolic 1 1
Age 68.1 ± 16.3 70.4 ± 12.1 0.40
Body weight (kg) 61.4 ± 9.6 62.5 ± 9.8 0.57
Gender (female/male) 16/39 (41%) 16/41 (39%) 0.90
Body mass index (kg/m2) 23.6 ± 3.0 23.9 ± 3.8 0.72
History of diabetes 19/55 (34.5%) 22/57 (38.6%) 0.67
Previous corticosteroid treatment 14/55 (25.4%) 16/57 (28.1%) 0.77
Use of inotropes 15/55 (27.3) 12/57 (21.1) 0.44
APACHE II score 20 (17 to 25) 21 (16.5 to 26.5) 0.94
Patients with total parenteral nutrition 2/55 (3.6%) 2/57 (3.5%) 0.97
Intake of nutrients
Carbohydrate (%) 54.3 ± 0.2 54.4 ± 0.2 0.84
Protein (%) 16.4 ± 0.1 16.4 ± 0.2 0.50
Fat (%) 29.3 ± 0.2 29.2 ± 0.8 0.55
At randomization
Blood glucose (mg/dl) 229.2 ± 39.3 231.1 ± 52.1 0.93
Serum hemoglobin (g/dl) 10.9 ± 2.2 10.8 ± 2.3 0.80
Serum ALT (U/l) 59.1 ± 79.3 63.8 ± 83.0 0.76
Serum total bilirubin (mg/dl) 1.1 ± 0.4 1.2 ± 0.4 0.88
UUN (g/BSA/24 hours) 7.0 ± 3.7 6.7 ± 3.8 0.78
Nitrogen balance (g/BSA/day) -4.8 ± 5.9 -4.7 ± 4.5 0.93
Serum albumin (mg/dl) 1,949.9 ± 376.0 1,955.4 ± 506.5 0.95
Serum prealbumin (mg/dl) 11.3 ± 5.2 11.2 ± 4.5 0.87
Data presented as n, mean ± standard deviation, or median (interquartile range). ALT, alanine aminotransferase; APACHE, Acute Physiology and Chronic Health
Evaluation; BSA, body surface area; CIT, conventional insulin therapy; MIT, moderate insulin therapy; UUN, urinary urea nitrogen.
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Discussion
The results of this study showed that MIT could signifi-
cantly improve nitrogen balance in the early stages of
critical illness. Patients treated with MIT had signifi-
cantly lower urinary nitrogen excretion and higher
serum albumin and prealbumin concentrations than
patients treated with CIT.
In the present study, both groups showed a negative
nitrogen balance during the study period. Although the
nitrogen balance was negative, both groups showed
improvement during the study period. Protein is rapidly
broken down in critically ill patients who are subjected to
high stress [18]. Hypermetabolism in patients under stress








































































Figure 2 Serum creatinine, creatinine clearance and 24-hour urine output on days 0, 3, 7, and 14. Top, serum creatinine; middle,
creatinine clearance; bottom, 24-hour urine output. Filled bars, patients receiving moderate insulin therapy (MIT group); open bars, patients
receiving conventional insulin therapy (CIT group).
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and a positive nitrogen balance is difficult to attain in
hypermetabolic patients [29]. Equilibrium between energy
intake and energy expenditure, early feeding, and a high-
protein diet may improve nitrogen balance [30-32]. In this
study, nitrogen balance was improved using moderate glu-
cose control. This improvement may have arisen from
higher dose insulin administered to the MIT group during
the hospital course. Higher infused doses of insulin can
result in a marked reduction in UUN excretion and a bet-
ter nitrogen balance [21].
Differences in nitrogen balance between the two treat-































































































Figure 3 Daily protein, calories intake, mean blood glucose levels and insulin dose. Daily protein intake (top), daily caloric intake (second
from top), mean blood glucose levels (second from bottom), and insulin dose (bottom) during the 2-week study period in the medical ICU.
Filled bars, moderate insulin therapy (MIT) group; open bars, conventional insulin therapy (CIT) group.
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critical illness, but decreased over time. This observation
may be related to the insulin dose. Differences in insulin
dose between the two groups were more significant in
the early stages than in the late stages.
The effect of insulin on protein metabolism appears
primarily to be due to inhibition of proteolysis
[33-35], although increased protein synthesis has been
reported [36]. In healthy subjects, insulin inhibits pro-
teolysis in a dose-dependent manner [37]. Insulin
binding to its receptors activates the insulin receptor
substrate pathway, leading to activation of protein
kinase; protein kinase B modulates enzyme activities
that affect nitric oxide generation and control protein
metabolism [38].
Insulin also has an anabolic effect that is beneficial to
critically ill patients; it may increase levels of insulin-like
growth factor (IGF)-1, a mediator of anabolic growth
hormone action, and decrease hepatic synthesis of IGF-
1 binding protein, leading to the increased bioavailability
of IGF-1 [39]. In a study involving rats, IGF-1 adminis-
tration significantly improved nitrogen balance [40].
Critical illness is characterized by hypermetabolism and
catabolism, leading to peripheral protein waste [41,42].
Proinflammatory mediators enhance catabolism and
hypermetabolism by inhibition of the growth hormone-
IGF-I-insulin axis [43-45]. Insulin improves hypermeta-
bolism by affecting proinflammatory cytokine production
and hepatic signal transcription factor expression [46]; it
attenuates the inflammatory response by decreasing the
proinflammatory cascade and increasing the anti-inflam-
matory cascade. By decreasing proinflammatory media-
tors, liver constitutive proteins such as albumin and
Table 2 Clinical outcomes
Outcome variable MIT group (n = 55) CIT group (n = 57) P value
Mean blood glucose (mg/dl) 125.3 ± 17.8 199.9 ± 30.2 < 0.01
Daily dose of insulin (unit/day) 82 (69 to 111) 37 (26 to 44) < 0.01
ICU days 14 (9 to 19) 15 (11 to 26) 0.26
Ventilator days 20 (11 to 30) 23 (11 to 43.5) 0.19
Hospital days 27 (15 to 36) 32 (18.5 to 51.3) 0.052
Acute renal injury 3/55 (5.5%) 7/57 (12.3%) 0.10
Bloodstream infection 1/55 (1.8%) 3/57 (5.3%) 0.33
Red-blood-cell blood transfusion 12/55 (21.8%) 15/57 (26.3%) 0.74
Gastrointestinal bleeding 7/55 (12.7%) 7/57 (12.3%) 0.83
Number of mild hypoglycemia 10/55 (18.2%) 6/57 (10.5%) 0.37
Rate of moderate hypoglycemia per 100 treatment days 2.4 1.5 0.18
Number of severe hypoglycemia 2/55 (3.6%) 1/57 (1.8%) 0.53
Rate of severe hypoglycemia per 100 treatment days 0.3 0.2 0.44
Hospital mortality rate 18/55 (32.7%) 28/57 (49.1%) 0.08



























Figure 4 Differences in mean daily insulin doses between moderate and conventional insulin therapy. Differences in mean daily insulin
doses between the moderate insulin therapy group and the conventional insulin therapy group.
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prealbumin are increased [47]. Inflammation reduces the
albumin concentration by decreasing its rate of synthesis
and increasing transfer of albumin out of the vascular
compartment [48].
Although our data and previous studies have shown that
insulin benefits protein metabolism, the extent to which
the benefit is derived from the correction of hyperglycemia
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Figure 5 Twenty-four-hour urinary urea nitrogen and nitrogen balance in patients receiving moderate or conventional insulin therapy.
Top, 24-hour urinary urea nitrogen (UUN); bottom, nitrogen balance. Data represent the mean ± standard deviation. A generalized linear model
of repeated measurements showed statistically significant differences between the two groups: #P = 0.027 for entire study period, *P < 0.05 for
day 3. BSA, body surface area; CIT, conventional insulin therapy; MIT, moderate insulin therapy.
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[49]. Van den Berghe and colleagues revealed that the low-
ering of blood glucose levels rather than the amount of
infused insulin is related to the effects of insulin therapy
on morbidity [7]. Acute hyperglycemia enhances proteoly-
sis in the entire body during hyperinsulinemia in normal
men [50]. Additionally, Whyte and colleagues demon-
strated that the administration of insulin which resulted in
supraphysiological concentrations did not attenuate pro-
tein breakdown and had no effect on the net protein bal-






















































Figure 6 Serum albumin and prealbumin levels in patients receiving moderate or conventional insulin therapy. Top, serum albumin;
bottom, serum prealbumin. Data represent the mean ± standard deviation. A generalized linear model of repeated measurements showed
statistically significant differences: #P = 0.047 for entire study period, ##P = 0.001 for entire study period, *P < 0.05 for day 3. CIT, conventional
insulin therapy; MIT, moderate insulin therapy.
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For patients receiving total parenteral nutrition, glu-
cose and lipid ratios influence the nitrogen balance. A
previous study showed that total parenteral nutrition at
a glucose/lipid ratio of 50/50 induced a significantly
higher nitrogen balance than an 80/20 ratio with an iso-
caloric isonitrogenous parenteral nutrition formula [52].
In our study, few patients received total parenteral
nutrition and they had a similar glucose/lipid ratio; thus,
the glucose/lipid ratio is not a confounding factor for
maintaining nitrogen balance.
A meta-analysis study showed that intensive insulin
therapy has no advantage in reducing the mortality rate,
but significantly increases the risk of hypoglycemia [53].
Our study demonstrated that most patients with hypo-
glycemia have a moderate form; severe hypoglycemia
was rarely observed. Target glucose levels in our study
were 120 to 140 mg/dl, which was higher than those in
intensive insulin therapy studies that had a target below
110 mg/dl [5,8]. The rate of severe hypoglycemia in the
intensive insulin therapy ranged from 5.1 to 28.6%
[5,9-13]. The rate of severe hypoglycemia was lower in
our study (3.6%) compared with previous studies that
adopted intensive glucose control. Moderate glucose
control was safer than intensive glucose control regard-
ing severe hypoglycemia.
There are some limitations to our study. First, this was
a single-center study limited to medical ICU patients
without chronic renal loss. These results do not repre-
sent all critically ill patients. Second, our study was not
double-blind because safe insulin titration required the
monitoring of blood glucose levels. Doctors and nurses
should be aware of target glucose control levels. All
patients did follow the same protocol, however, except
for those following the glucose control protocol. Third,
the study group was only moderately sized. Some para-
meters, such as clinical outcomes, did not show a signif-
icant difference due to the small sample size. Further
studies are needed to examine larger sample sizes.
Conclusion
Patients treated with MIT had significantly lower urin-
ary nitrogen excretion and higher serum albumin and
prealbumin concentrations compared with patients trea-
ted with CIT. Moderate glucose control can result in a
less negative nitrogen balance in medical ICU patients.
This difference was more significant in the early stages
compared with the late stages of critical illness.
Key messages
• Patients treated with MIT had significantly lower
urinary nitrogen excretion and higher serum albu-
min and prealbumin concentrations than patients
treated with CIT.
• Moderate glucose control can result in a less nega-
tive nitrogen balance; this may be related to insulin.
• The difference of nitrogen balance between MIT
and CIT was more significant in the early stages
compared with the late stages of critical illness in
medical ICU patients.
Additional material
Additional file 1: Appendix 1 showing the insulin protocol.
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